Cargando…

A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model

BACKGROUND: Conventional immunotherapy for glioma is not only expensive but also demonstrates less-than-desired clinical efficacy. In this study, we evaluated the immunotherapeutic efficacy of a tumor cell lysate-based hybrid glioma vaccine developed using a molecular-based approach. METHODS: First,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin-Long, Zeng, Shan, He, Hai-Ping, Zeng, Xu, Peng, Li-Lei, Chen, Li-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438187/
https://www.ncbi.nlm.nih.gov/pubmed/32884294
http://dx.doi.org/10.2147/OTT.S259516
_version_ 1783572753095327744
author Li, Xin-Long
Zeng, Shan
He, Hai-Ping
Zeng, Xu
Peng, Li-Lei
Chen, Li-Gang
author_facet Li, Xin-Long
Zeng, Shan
He, Hai-Ping
Zeng, Xu
Peng, Li-Lei
Chen, Li-Gang
author_sort Li, Xin-Long
collection PubMed
description BACKGROUND: Conventional immunotherapy for glioma is not only expensive but also demonstrates less-than-desired clinical efficacy. In this study, we evaluated the immunotherapeutic efficacy of a tumor cell lysate-based hybrid glioma vaccine developed using a molecular-based approach. METHODS: First, the ability of the autologous (9L-cell lysate) and allogeneic (C6-cell lysate) vaccines against glioma, individually and in combination, to activate Fischer344 rat dendritic cells (DCs) was determined. Next, the activated DCs were co-cultured with T lymphocytes and screened for the optimal DC-to-T-cell ratio. The in vitro efficacy of the DC/T-cell vaccine formulations subjected to different immunogen treatments and co-cultured with glioma cells was evaluated based on glioma cell viability and monocyte chemoattractant protein (MCP)-2 and interferon (IFN)-γ secretion. Subsequently, the efficacy of the 9L + C6 hybrid vaccine was evaluated in 32 glioma rat models, randomly allocated to the following five treatment groups: blank control, tumor, vaccine treatment, thymosin treatment, and vaccine + thymosin treatment (combined treatment). Changes in survival duration, intracranial tumor volume, peripheral blood immune-cell (CD4+ T, CD8+ T, and natural killer [NK] cell) count, and serum cytokine (interleukin [IL]-2, IL-10) levels were assessed in these groups. RESULTS: The hybrid vaccine demonstrated the highest glioma cell apoptosis and the lowest cell viability and promoted MCP-2 and IFN-γ secretion in vitro. The vaccine treatment and combined treatment groups demonstrated longer survival duration, lower intracranial tumor volume, and higher immune cell glioma tissue infiltration and IL-2 secretion than the untreated tumor group, indicating the vaccine’s good in vivo efficacy. Thymosin treatment had minimal effect in enhancing anti-glioma immunity. CONCLUSION: We demonstrated the feasibility of combining autologous and allogeneic tumor cell lysates to stimulate specific host cell immune response against glioma cells. The good clinical efficacy of our developed glioma hybrid vaccine in rat models suggests its potential clinical application.
format Online
Article
Text
id pubmed-7438187
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74381872020-09-02 A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model Li, Xin-Long Zeng, Shan He, Hai-Ping Zeng, Xu Peng, Li-Lei Chen, Li-Gang Onco Targets Ther Original Research BACKGROUND: Conventional immunotherapy for glioma is not only expensive but also demonstrates less-than-desired clinical efficacy. In this study, we evaluated the immunotherapeutic efficacy of a tumor cell lysate-based hybrid glioma vaccine developed using a molecular-based approach. METHODS: First, the ability of the autologous (9L-cell lysate) and allogeneic (C6-cell lysate) vaccines against glioma, individually and in combination, to activate Fischer344 rat dendritic cells (DCs) was determined. Next, the activated DCs were co-cultured with T lymphocytes and screened for the optimal DC-to-T-cell ratio. The in vitro efficacy of the DC/T-cell vaccine formulations subjected to different immunogen treatments and co-cultured with glioma cells was evaluated based on glioma cell viability and monocyte chemoattractant protein (MCP)-2 and interferon (IFN)-γ secretion. Subsequently, the efficacy of the 9L + C6 hybrid vaccine was evaluated in 32 glioma rat models, randomly allocated to the following five treatment groups: blank control, tumor, vaccine treatment, thymosin treatment, and vaccine + thymosin treatment (combined treatment). Changes in survival duration, intracranial tumor volume, peripheral blood immune-cell (CD4+ T, CD8+ T, and natural killer [NK] cell) count, and serum cytokine (interleukin [IL]-2, IL-10) levels were assessed in these groups. RESULTS: The hybrid vaccine demonstrated the highest glioma cell apoptosis and the lowest cell viability and promoted MCP-2 and IFN-γ secretion in vitro. The vaccine treatment and combined treatment groups demonstrated longer survival duration, lower intracranial tumor volume, and higher immune cell glioma tissue infiltration and IL-2 secretion than the untreated tumor group, indicating the vaccine’s good in vivo efficacy. Thymosin treatment had minimal effect in enhancing anti-glioma immunity. CONCLUSION: We demonstrated the feasibility of combining autologous and allogeneic tumor cell lysates to stimulate specific host cell immune response against glioma cells. The good clinical efficacy of our developed glioma hybrid vaccine in rat models suggests its potential clinical application. Dove 2020-08-14 /pmc/articles/PMC7438187/ /pubmed/32884294 http://dx.doi.org/10.2147/OTT.S259516 Text en © 2020 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Xin-Long
Zeng, Shan
He, Hai-Ping
Zeng, Xu
Peng, Li-Lei
Chen, Li-Gang
A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model
title A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model
title_full A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model
title_fullStr A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model
title_full_unstemmed A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model
title_short A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model
title_sort hybrid glioma tumor cell lysate immunotherapy vaccine demonstrates good clinical efficacy in the rat model
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438187/
https://www.ncbi.nlm.nih.gov/pubmed/32884294
http://dx.doi.org/10.2147/OTT.S259516
work_keys_str_mv AT lixinlong ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT zengshan ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT hehaiping ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT zengxu ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT penglilei ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT chenligang ahybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT lixinlong hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT zengshan hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT hehaiping hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT zengxu hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT penglilei hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel
AT chenligang hybridgliomatumorcelllysateimmunotherapyvaccinedemonstratesgoodclinicalefficacyintheratmodel